T2 Biosystems to Present at the Canaccord Genuity Medical Technologies & Diagnostics Forum

LEXINGTON, Mass., Nov. 11, 2016 -- T2 Biosystems, Inc. (NASDAQ:TTOO) today announced that John McDonough, president and chief executive officer, and Shawn Lynch, chief financial officer, are scheduled to attend and present at the Canaccord Genuity Medical Technologies & Diagnostics Forum on Thursday, November 17, 2016, at 2:00 p.m. ET in New York City.

A live, listen-only webcast of the presentation may be accessed by visiting the Investors/Events & Presentations section of the Company’s website at www.t2biosystems.com.  A replay of the webcast will be available shortly after the conclusion of the presentation and will be archived on the Company's website for 30 days.

About T2 Biosystems
T2 Biosystems is focused on developing innovative diagnostic products to improve patient health. With two FDA-cleared products targeting sepsis and a range of additional products in development, T2 Biosystems is an emerging leader in the field of in vitro diagnostics. The Company is utilizing its proprietary T2 Magnetic Resonance platform, or T2MR^®, to develop a broad set of applications aimed at lowering mortality rates, improving patient outcomes and reducing the cost of healthcare by helping medical professionals make targeted treatment decisions earlier. T2MR enables the fast and sensitive detection of pathogens, biomarkers and other abnormalities in a variety of unpurified patient sample types, including whole blood, eliminating the time-consuming sample prep required in current methods. For more information, please visit www.t2biosystems.com.

Media Contact:
Susan Heins, 
Pure Communications
[email protected]
864-286-9597

Investor Contact:
Matt Clawson,
Pure Communications
[email protected]
949-370-8500